atezolizumab + obinutuzumab + cyclophosphamide + doxorubicin + vincristine + prednisone

Atezolizumab + obinutuzumab + cyclophosphamide + doxorubicin + vincristine + prednisone is a combination regimen that merges immunotherapy and antibody therapy (atezolizumab, an anti-PD-L1 antibody; obinutuzumab, an anti-CD20 antibody) with multi-agent cytotoxic chemotherapy (cyclophosphamide, doxorubicin, vincristine) and corticosteroid therapy (prednisone). Atezolizumab blocks PD-L1 to enhance antitumor immune responses. Obinutuzumab targets CD20 on B cells leading to cell destruction by immune-mediated mechanisms. Cyclophosphamide is an alkylating agent causing DNA crosslinking; doxorubicin is a topoisomerase II inhibitor producing DNA damage; vincristine is a vinca alkaloid that inhibits microtubule assembly, and prednisone is a synthetic glucocorticoid with antitumor and anti-inflammatory effects. This combination is designed for hematologic malignancies, especially lymphomas. There are reports and ongoing studies involving similar regimens (with venetoclax instead of chemotherapy), but data specifically for the exact six-drug combination are limited; the combination’s rationale is to increase cytotoxicity and immune-mediated killing of malignant B cells[1][2][4][8].